FIELD: pharmaceuticals.
SUBSTANCE: invention relates to a compound of formulas I and II or a pharmaceutically acceptable salt thereof, a pharmaceutical composition, use in the treatment of diseases in which a capsid protein assembly inhibitor is useful, in particular diseases caused by hepatitis B virus (HBV) infection.
EFFECT: new compounds of formulas I and II, effective inhibitors of capsid protein assembly, which can be useful for the treatment of diseases caused by hepatitis B virus (HBV) infection, have been obtained.
9 cl, 10 tbl, 6 ex
| Title | Year | Author | Number |
|---|---|---|---|
| CLASS OF CONDENSED RING COMPOUNDS AND THEIR PRODUCTION AND USE | 2021 |
|
RU2831125C1 |
| DERIVATIVE OF PYRROLOPYRIMIDINE AND APPLICATION THEREOF | 2020 |
|
RU2780254C1 |
| HETEROCYCLIC COMPOUNDS AND THEIR APPLICATION | 2016 |
|
RU2744897C2 |
| SUBSTITUTED AROMATIC DERIVATIVE WITH CONDENSED RINGS AND COMPOSITION INCLUDING IT AND THEIR USE | 2020 |
|
RU2811484C1 |
| HETEROARYL PIPERAZINE DERIVATIVE, METHOD FOR ITS PREPARATION AND APPLICATION IN MEDICINE | 2018 |
|
RU2745431C1 |
| 3,4-DIHYDROISOQUINOLINE COMPOUND AND USE THEREOF | 2021 |
|
RU2825312C1 |
| BICYCLIC COMPOUNDS AS ALLOSTERIC SHP2 INHIBITORS | 2018 |
|
RU2776846C2 |
| TRICYCLIC COMPOUND AND JAK INHIBITOR | 2015 |
|
RU2674262C2 |
| SYNTHESIS OF NEW EP4 ANTAGONIST AND APPLICATION IN CANCER AND INFLAMMATION | 2021 |
|
RU2804153C1 |
| COMBINED TREATMENT BY A TOLL-LIKE RECEPTOR (TLR7) AGONIST AND A HEPATITIS B VIRUS CAPSID ASSEMBLY INHIBITOR | 2016 |
|
RU2718917C2 |
